Search results for "Antiretrovirals"
showing 2 items of 2 documents
Occurrence of antibiotics and antiretroviral drugs in source-separated urine, groundwater, surface water and wastewater in the peri-urban area of Chu…
2020
Recently, there has been an increased interest in bridging the knowledge gap in the occurrence and fate of pharmaceuticals in African urban water cycles. In this study, the occurrence of 7 antibiotics and 3 antiretrovirals in source-separated urine, groundwater, wastewater and surface water of the peri-urban area of Chunga in Lusaka, Zambia, was studied. In groundwater, the pharmaceuticals were only sporadically present with 4 antibiotics and 1 antiretroviral detected. The concentration of the antibiotics ranged from below limit of quantification (<LOQ) to 880 ng/L, with sulfamethoxazole having the highest detection frequency of 42.3%. In the surface water, a comparatively high concentrati…
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…
2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…